Provided by Tiger Trade Technology Pte. Ltd.

Indaptus Therapeutics, Inc.

1.29
-0.0900-6.52%
Post-market: 1.300.0100+0.78%19:34 EDT
Volume:1.14M
Turnover:1.50M
Market Cap:171.57M
PE:-2.71
High:1.58
Open:1.39
Low:1.18
Close:1.38
52wk High:8.57
52wk Low:0.9200
Shares:133.00M
Float Shares:23.24M
Volume Ratio:0.42
T/O Rate:4.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4756
EPS(LYR):-21.5800
ROE:-318.04%
ROA:-98.08%
PB:15.09
PE(LYR):-0.06

Loading ...

Company Profile

Company Name:
Indaptus Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
5
Office Location:
Three Columbus Circle,15th Floor,New York,New York,United States
Zip Code:
10019
Fax:
- -
Introduction:
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Directors

Name
Position
Junyi Dai
Chairman,Chief Executive Officer and Director
David Natan
Independent Director
Jerome Jabbour
Independent Director
Johnny Fox Arrowsmith
Independent Director
Qinglai Lu
Independent Director
Tim Ruan
Independent Director

Shareholders

Name
Position
Junyi Dai
Chairman,Chief Executive Officer and Director
Yu Ding
Chief Financial Officer